BioMarin submits FDA sNDA for VOXZOGO in hypochondroplasia
BMRN•BioMarin filed an sNDA with the FDA seeking to expand VOXZOGO to treat hypochondroplasia. If cleared, it could be the first targeted therapy for the condition, with a potential 2027 launch; submissions to the EMA and other health authorities remain on track.
1. FDA application filed
BioMarin filed an sNDA seeking FDA approval to expand VOXZOGO to treat hypochondroplasia. Submissions to the EMA and other health authorities remain on track. If cleared, VOXZOGO would be the first targeted therapy for hypochondroplasia, with a potential 2027 launch.
